多发性骨髓瘤中tRNA衍生片段的小RNA测序与临床评估:线粒体i-tRFHisGTG缺失导致患者治疗结局不良
研究对骨髓CD138+浆细胞行小RNA测序,发现线粒体内部tRFHisGTG(mt-i-tRFHisGTG)在多发性骨髓瘤(MM)中较冒烟型MM/MGUS显著失调。筛查队列147例MM患者经RT-qPCR定量,mt-i-tRFHisGTG降低与骨病(p=0.010)、骨质溶解(p=0.023)及一线化疗后短期疾病进展风险显著升高相关(HR=1.954;p=0.036),且独立于临床数据。
要点
- 小RNA测序显示mt-i-tRFHisGTG在MM较sMM/MGUS显著失调。
- 筛查队列147例MM患者中,mt-i-tRFHisGTG降低与骨病(p=0.010)和骨质溶解(p=0.023)相关。
- mt-i-tRFHisGTG降低与一线化疗后短期疾病进展风险升高独立相关(HR=1.954;p=0.036)。
核心结论
- mt-i-tRFHisGTG缺失是MM患者治疗后进展的强独立指标,可带来优于疾病既定标志物的风险分层。
研究设计与样本
- 研究对骨髓CD138+浆细胞行小RNA测序以分析tRF谱,比较MM与sMM/MGUS。
- 筛查队列由147例MM患者组成,采用RT-qPCR定量mt-i-tRFHisGTG水平。
- 以疾病进展为临床终点进行生存分析,并通过bootstrap和决策曲线分析进行内部验证。
主要发现
- 小RNA测序显示线粒体内部tRFHisGTG(mt-i-tRFHisGTG)在MM较sMM/MGUS显著失调。
- 筛查队列中mt-i-tRFHisGTG降低与骨病(p=0.010)和骨质溶解(p=0.023)相关。
- mt-i-tRFHisGTG降低与一线化疗后短期疾病进展风险显著升高独立相关(HR=1.954;p=0.036)。
- mt-i-tRFHisGTG拟合的多变量模型对MM患者治疗结局和预后的风险分层优于疾病既定标志物。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite the substantial progress in multiple myeloma (MM) therapy nowadays, treatment resistance and disease relapse remain major clinical hindrances. Herein, we have investigated tRNA-derived fragment (tRF) profiles in MM and precursor stages (smoldering MM/sMM; monoclonal gammopathy of undetermined significance/MGUS), aiming to unveil potential MM-related tRFs in ameliorating MM prognosis and risk stratification. Small RNA-seq was performed to profile tRFs in bone marrow CD138+ plasma cells, revealing the significant deregulation of the mitochondrial internal tRFHisGTG (mt-i-tRFHisGTG) in MM versus sMM/MGUS. The screening cohort of the study consisted of 147 MM patients, and mt-i-tRFHisGTG levels were quantified by RT-qPCR. Disease progression was assessed as clinical end-point for survival analysis, while internal validation was performed by bootstrap and decision curve analyses. Screening cohort analysis highlighted the potent association of reduced mt-i-tRFHisGTG levels with patients' bone disease (p = 0.010), osteolysis (p = 0.023) and with significantly higher risk for short-term disease progression following first-line chemotherapy, independently of patients' clinical data (HR = 1.954; p = 0.036). Additionally, mt-i-tRFHisGTG-fitted multivariate models led to superior risk stratification of MM patients' treatment outcome and prognosis compared to disease-established markers. Notably, our study highlighted mt-i-tRFHisGTG loss as a powerful independent indicator of post-treatment progression of MM patients, leading to superior risk stratification of patients' treatment outcome.
引用
- Soureas K, Papadimitriou MA, Malandrakis P, et al. Small RNA-seq and clinical evaluation of tRNA-derived fragments in multiple myeloma: Loss of mitochondrial i-tRFHisGTG results in patients' poor treatment outcome. Br J Haematol. 2024. PMID: 38414235. doi:10.1111/bjh.19332
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。